CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Aprepitant +1 moredrug
Likely dose
Aprepitant 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01963793
NCT01963793Phase 2Completed
CompareCT.gov

Topical Aprepitant in Prurigo Patients An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo

LEO Pharma·interventional·Posted Oct 16, 2013·Updated Mar 10, 2025

In Brief

A Phase 2 clinical trial evaluating Aprepitant and Placebo for Pruritus. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Topical Aprepitant in Prurigo Patients - An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 16, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.7 years ago

Interventions

Aprepitantdrug

Aprepitant gel (10 mg/g)

Placebodrug

gel without active component